QNRX

SEC source: 0001104659-26-104403 · tm2624615-2_4seq1.xml · derivative · entry 2

Lawlor Sally Bridget · CIK 0002084407 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,122

Underlying: ADS · 5,122 shares

Expires not disclosed

F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F2 · price: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F4 · derivative.expiration_date: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

SEC source: 0001104659-26-104403 · tm2624615-2_4seq1.xml · nonDerivative · entry 1

Lawlor Sally Bridget · CIK 0002084407 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,684

F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

SEC source: 0001104659-26-104405 · tm2624615-4_4seq1.xml · derivative · entry 2

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,245

Underlying: ADS · 10,245 shares

Expires not disclosed

F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F2 · price: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F4 · derivative.expiration_date: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

SEC source: 0001104659-26-104405 · tm2624615-4_4seq1.xml · nonDerivative · entry 1

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,709

F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

SEC source: 0001104659-26-104402 · tm2624615-1_4seq1.xml · derivative · entry 2

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,073

Underlying: ADS · 3,073 shares

Expires not disclosed

F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F2 · price: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F4 · derivative.expiration_date: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

SEC source: 0001104659-26-104402 · tm2624615-1_4seq1.xml · nonDerivative · entry 1

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,364

F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

SEC source: 0001104659-26-104404 · tm2624615-3_4seq1.xml · derivative · entry 2

Myers Michael · CIK 0001959547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,245

Underlying: ADS · 10,245 shares

Expires not disclosed

F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F2 · price: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F4 · derivative.expiration_date: The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.

F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

SEC source: 0001104659-26-104404 · tm2624615-3_4seq1.xml · nonDerivative · entry 1

Myers Michael · CIK 0001959547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,713

F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

F2 · kind: Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

SEC source: 0001104659-26-103374 · tm2624320-1_4seq1.xml · nonDerivative · entry 1

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,218

F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

F2 · kind: On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $161,461 of accrued interest outstanding ("Outstanding Debt") owed in connection with a note previously purchased by the Reporting Person was exchanged for 31,352 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.

SEC source: 0001104659-26-103376 · tm2624320-2_4seq1.xml · nonDerivative · entry 1

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,243

F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

F2 · kind: On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $177,849 of accrued interest outstanding ("Outstanding Debt") owed in connection with a note previously purchased by the Reporting Person was exchanged for 34,534 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.

SEC source: 0001104659-26-011610 · tm265448-2_4seq1.xml · derivative · entry 1

SEMBER MICHAEL T · CIK 0001107486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,141

Underlying: ADS · 8,141 shares

Expires 2036-02-04

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-26-011623 · tm265448-8_4seq1.xml · derivative · entry 1

Lawlor Sally Bridget · CIK 0002084407 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,250

Underlying: ADS · 85,250 shares

Expires 2036-02-04

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-26-011615 · tm265448-4_4seq1.xml · derivative · entry 1

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 318,750

Underlying: ADS · 318,750 shares

Expires 2036-02-04

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-26-011608 · tm265448-1_4seq1.xml · derivative · entry 1

Leong Natalie Ee Mun · CIK 0001959318 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,211

Underlying: ADS · 12,211 shares

Expires 2036-02-04

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-26-011617 · tm265448-6_4seq1.xml · derivative · entry 1

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,709

Underlying: ADS · 21,709 shares

Expires 2036-02-04

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-26-011622 · tm265448-7_4seq1.xml · derivative · entry 1

Cooper Joseph Patrick · CIK 0001368711 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,141

Underlying: ADS · 8,141 shares

Expires 2036-02-04

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-26-011616 · tm265448-5_4seq1.xml · derivative · entry 1

Myers Michael · CIK 0001959547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 318,750

Underlying: ADS · 318,750 shares

Expires 2036-02-04

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-26-011613 · tm265448-3_4seq1.xml · derivative · entry 1

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,709

Underlying: ADS · 21,709 shares

Expires 2036-02-04

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of February 4, 2027, 2028 and 2029 and 40% vesting on February 4, 2030.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-118190 · tm2532695-1_4seq1.xml · derivative · entry 1

Lawlor Sally Bridget · CIK 0002084407 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,330

Underlying: ADS · 10,330 shares

Expires 2035-12-01

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · date: The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F3 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-099782 · tm2528832-1_4seq1.xml · derivative · entry 5

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,152

Underlying: ADS · 15,152 shares

Expires not disclosed

F2 · kind: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F7 · derivative.expiration_date: The Series K Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the Company's sale of a Priority Review Voucher (PRV).

F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

SEC source: 0001104659-25-099782 · tm2528832-1_4seq1.xml · derivative · entry 4

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,152

Underlying: ADS · 15,152 shares

Expires not disclosed

F2 · kind: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F6 · derivative.expiration_date: The Series J Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome.

F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

SEC source: 0001104659-25-099782 · tm2528832-1_4seq1.xml · derivative · entry 3

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,152

Underlying: ADS · 15,152 shares

Expires not disclosed

F2 · kind: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F5 · derivative.expiration_date: The Series I Warrants will expire as follows: (i) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the monotherapy pivotal trial of QRX003 for the treatment of Netherton Syndrome, and (ii) 50% of the Series I Warrants will expire on the earlier of (A) five (5) years from the Closing Date or (B) 30 days after the Company's public announcement that the primary endpoint has been met in the adjuvant pivotal trial of QRX003 for the treatment of Netherton Syndrome.

F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

SEC source: 0001104659-25-099782 · tm2528832-1_4seq1.xml · derivative · entry 2

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,152

Underlying: ADS · 15,152 shares

Expires not disclosed

F2 · kind: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

F4 · derivative.expiration_date: The Series H Warrants will expire on the earlier of (i) five (5) years from the Closing Date or (ii) 30 days after the Company's public announcement that the Company has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome.

F1 · derivative.underlying: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

SEC source: 0001104659-25-099782 · tm2528832-1_4seq1.xml · nonDerivative · entry 1

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,153

F1 · security: Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

F2 · kind: Each ADS purchased together with a Series H Warrant, a Series I Warrant, a Series J Warrant and a Series K Warrant to purchase one ADS in the Issuer's private placement which closed on October 14, 2025, at a combined price of $8.49. The Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants are collectively referred to as the "Warrants."

SEC source: 0001104659-25-082518 · tm2524172-3_4seq1.xml · derivative · entry 1

Leong Natalie Ee Mun · CIK 0001959318 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,105

Underlying: ADS · 4,105 shares

Expires 2035-05-28

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · date: The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F3 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-082515 · tm2524172-2_4seq1.xml · derivative · entry 1

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,682

Underlying: ADS · 13,682 shares

Expires 2035-05-28

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · date: The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F3 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-082511 · tm2524172-1_4seq1.xml · derivative · entry 1

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,682

Underlying: ADS · 13,682 shares

Expires 2035-05-28

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · date: The option grant was approved by the Compensation Committee and the Board on May 29, 2025, subject to shareholder approval. The Company's shareholder's approved this option grant on August 21, 2025.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F3 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-055626 · tm2516320-1_4seq1.xml · derivative · entry 1

SEMBER MICHAEL T · CIK 0001107486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,760

Underlying: ADS · 7,760 shares

Expires 2035-05-29

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-055633 · tm2516320-6_4seq1.xml · derivative · entry 1

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,039

Underlying: ADS · 42,039 shares

Expires 2035-05-29

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-055631 · tm2516320-5_4seq1.xml · derivative · entry 1

Leong Natalie Ee Mun · CIK 0001959318 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,760

Underlying: ADS · 7,760 shares

Expires 2035-05-29

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-055634 · tm2516320-7_4seq1.xml · derivative · entry 1

Myers Michael · CIK 0001959547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,039

Underlying: ADS · 42,039 shares

Expires 2035-05-29

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-055629 · tm2516320-3_4seq1.xml · derivative · entry 1

LANGER DENNIS · CIK 0001274225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,760

Underlying: ADS · 7,760 shares

Expires 2035-05-29

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-055627 · tm2516320-2_4seq1.xml · derivative · entry 1

Cooper Joseph Patrick · CIK 0001368711 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,760

Underlying: ADS · 7,760 shares

Expires 2035-05-29

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-055943 · tm2516320-4_4seq1.xml · derivative · entry 1

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,760

Underlying: ADS · 7,760 shares

Expires 2035-05-29

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.

SEC source: 0001104659-25-059530 · tm2518028-3_4aseq1.xml · derivative · entry 1

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,857

Underlying: ADS · 42,857 shares

Expires 2035-05-29

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

SEC source: 0001104659-25-059529 · tm2518028-4_4aseq1.xml · derivative · entry 1

Myers Michael · CIK 0001959547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,857

Underlying: ADS · 42,857 shares

Expires 2035-05-29

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of May 29, 2026, 2027 and 2028 and 40% vesting on May 29, 2029.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer. On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025.

SEC source: 0001104659-24-132190 · tm2431988-4_4seq1.xml · derivative · entry 3

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 555,556

Underlying: ADS · 555,556 shares

Expires 2029-12-24

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap.

SEC source: 0001104659-24-132190 · tm2431988-4_4seq1.xml · derivative · entry 2

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 555,556

Underlying: ADS · 555,556 shares

Expires 2026-12-23

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap.

SEC source: 0001104659-24-132190 · tm2431988-4_4seq1.xml · nonDerivative · entry 1

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 602,648

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

SEC source: 0001104659-24-132185 · tm2431988-1_4seq1.xml · derivative · entry 3

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: ADS · 100,000 shares

Expires 2029-12-24

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap.

SEC source: 0001104659-24-132185 · tm2431988-1_4seq1.xml · derivative · entry 2

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: ADS · 100,000 shares

Expires 2026-12-23

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap.

SEC source: 0001104659-24-132185 · tm2431988-1_4seq1.xml · nonDerivative · entry 1

Culverwell Anthony James · CIK 0001693548 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,317

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

SEC source: 0001104659-24-132188 · tm2431988-3_4seq1.xml · derivative · entry 3

Myers Michael · CIK 0001959547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 555,556

Underlying: ADS · 555,556 shares

Expires 2029-12-24

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap.

SEC source: 0001104659-24-132188 · tm2431988-3_4seq1.xml · derivative · entry 2

Myers Michael · CIK 0001959547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 555,556

Underlying: ADS · 555,556 shares

Expires 2026-12-23

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap.

SEC source: 0001104659-24-132188 · tm2431988-3_4seq1.xml · nonDerivative · entry 1

Myers Michael · CIK 0001959547 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 602,808

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

SEC source: 0001104659-24-132187 · tm2431988-2_4seq1.xml · derivative · entry 3

Dunn Gordon · CIK 0001958139 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,221

Underlying: ADS · 122,221 shares

Expires 2029-12-24

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap.

SEC source: 0001104659-24-132187 · tm2431988-2_4seq1.xml · derivative · entry 2

Dunn Gordon · CIK 0001958139 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,221

Underlying: ADS · 122,221 shares

Expires 2026-12-23

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F2 · price: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

F3 · derivative.exercise_date: The Warrants were exercisable immediately, subject to a beneficial ownership cap.

SEC source: 0001104659-24-132187 · tm2431988-2_4seq1.xml · nonDerivative · entry 1

Dunn Gordon · CIK 0001958139 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 151,077

F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F2 · kind: Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."

SEC source: 0001104659-24-127238 · tm2430519-4_4seq1.xml · derivative · entry 1

SEMBER MICHAEL T · CIK 0001107486 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,714

Underlying: ADS · 50,714 shares

Expires 2034-12-09

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

SEC source: 0001104659-24-127239 · tm2430519-5_4seq1.xml · derivative · entry 1

Carter Denise P. · CIK 0001958621 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 536,609

Underlying: ADS · 536,609 shares

Expires 2034-12-09

F1 · derivative.exercise_price: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F1 · shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F2 · derivative.exercise_date: The option vests in four annual installments with 20% vesting on each of December 9, 2025, 2026 and 2027 and 40% vesting on December 9, 2028.

F1 · derivative.underlying: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F1 · derivative.underlying_shares: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.

F1 · balance_after: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.